Heidelberg, March 12, 2007 - Apogenix GmbH, a biopharmaceutical company developing novel drugs based on the targeted modulation of apoptosis (programmed cell death), today announced that it has been granted 0.9 million Euro in research funding from the German Federal Ministry of Education and Research (BMBF). The research grant is part of the ministry’s program to support „Innovative Molecular and Cellular-Based Therapies“.
